Vivos Therapeutics Debt to Equity vs. Market Capitalization

VVOS -  USA Stock  

USD 2.65  0.10  3.64%

For Vivos Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vivos Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vivos Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vivos Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vivos Therapeutics over time as well as its relative position and ranking within its peers. Also, please take a look at World Market Map.

Vivos Current Profitability Trends 

 
Refresh
Is Vivos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vivos Therapeutics. If investors know Vivos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vivos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vivos Therapeutics is measured differently than its book value, which is the value of Vivos that is recorded on the company's balance sheet. Investors also form their own opinion of Vivos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vivos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vivos Therapeutics' market value can be influenced by many factors that don't directly affect Vivos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Vivos Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Vivos Therapeutics Market Capitalization vs. Debt to Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Vivos Therapeutics's current stock value. Our valuation model uses many indicators to compare Vivos Therapeutics value to that of its competitors to determine the firm's financial worth.
Vivos Therapeutics is rated below average in debt to equity category among related companies. It is rated below average in market capitalization category among related companies creating about  1,972,647,029  of Market Capitalization per Debt to Equity. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vivos Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vivos Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vivos Therapeutics' earnings, one of the primary drivers of an investment's value.

Vivos Market Capitalization vs. Debt to Equity

Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Vivos Therapeutics 
D/E 
 = 
Total Debt 
Total Equity 
0.034 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Vivos Therapeutics 
Market Cap 
 = 
Shares Outstanding 
X  
Share Price 
67.07 M
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Vivos Market Capitalization vs Competition

Vivos Therapeutics is rated below average in market capitalization category among related companies. Market capitalization of Medical Devices industry is at this time estimated at about 720.05 Billion. Vivos Therapeutics adds roughly 67.07 Million in market capitalization claiming only tiny portion of all equities under Medical Devices industry.
Capitalization  Revenue  Total debt  Workforce  Valuation

Vivos Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Vivos Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vivos Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Vivos Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Vivos Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea . Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. Vivos Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Vivos Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Vivos Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vivos Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vivos Therapeutics' important profitability drivers and their relationship over time.

Use Vivos Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vivos Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vivos Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Vivos Therapeutics Pair Trading

Vivos Therapeutics Pair Trading Analysis

Correlation analysis and pair trading evaluation for Vivos Therapeutics and Abbott Laboratories. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  

Use Investing Themes to Complement your Vivos Therapeutics position

In addition to having Vivos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run World Allocation Thematic Idea Now

World Allocation
World Allocation Theme
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. World Allocation theme has 40 constituents.
View All  Next Launch World Allocation
Also, please take a look at World Market Map. Note that the Vivos Therapeutics information on this page should be used as a complementary analysis to other Vivos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Vivos Stock analysis

When running Vivos Therapeutics price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
To fully project Vivos Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Vivos Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Vivos Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Vivos Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Vivos Therapeutics investors may work on each financial statement separately, they are all related. The changes in Vivos Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vivos Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.